Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Scientists develop vaccine for fusobacterium necrophorum
Fusobacterium necrophorum causes infection in livestock and people, but scientists at Kansas State University have found a way to protect animals and humans from the virus.

Bacterium affects both livestock and people

A vaccine that could provide effective, antibiotic-free prevention of Fusobacterium infection has been developed by scientists at Kansas State University.

Fusobacterium necrophroum infection affects both livestock and people. Currently, antibiotics are used to control the bacterium, but researchers say the new vaccine takes an altogether different approach.

"The Food and Drug Administration has prevented the use of many antibiotics in cattle, especially those similar to ones with human applications, so this vaccine is an alternative,” commented Sanjeev K. Narayanan, professor of diagnostic medicine and pathobiology. 

“This way, we don't expose people's food to as many antibiotics, so the vaccine protects both animals and humans."

The vaccine uses a two-pronged approach. It first immunises the animal against leukotoxins, which kill white blood cells and Kupffer cells - the liver’s natural weapons against bacteria.

The team found that Fusobacterium bacterium is able to survive in the liver because it produces leukotoxins. By immunising, if the bacterium enters the liver, there are antibodies built up against it, and the antibodies will neutralise the toxin.

The second element of the vaccine was developed in the lab, where the team identified the protein that allows the bacterium to attach to the walls of the rumen and the liver.

They were then able to identify a major protein in Fusobacterium necrophorum that is responsible for attaching to organs. Antibodies generated in the animal against the protein will prevent bacterial attachment.

"If you can prevent attachment, you can prevent infection," said T.G Nagaraja, a distinguished professor of microbiology. "That's why this patented vaccine uses a two-pronged approach."

The team says the vaccine is currently in testing for cattle, and may eventually be available also for sheep and for people.

Image (C) Kansas State University

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.